Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $25.40.

Several equities analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Monday. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Oppenheimer set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th.

Kura Oncology Trading Down 3.9%

Shares of KURA stock opened at $13.06 on Friday. Kura Oncology has a 1-year low of $7.36 and a 1-year high of $13.90. The firm has a market cap of $1.16 billion, a PE ratio of -3.88 and a beta of 0.38. The company has a 50-day moving average of $10.74 and a two-hundred day moving average of $9.58. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, analysts predict that Kura Oncology will post -3.23 EPS for the current year.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
• Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
• Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
• Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
• Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
• Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale

Insider Activity

In other news, insider Teresa Brophy Bair sold 31,487 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Troy Edward Wilson acquired 100,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were purchased at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the transaction, the chief executive officer owned 479,194 shares in the company, valued at approximately $5,937,213.66. The trade was a 26.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 120,761 shares of company stock worth $1,283,346 over the last three months. Insiders own 7.60% of the company’s stock.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its position in shares of Kura Oncology by 968.0% during the 2nd quarter. California State Teachers Retirement System now owns 1,017,939 shares of the company’s stock worth $11,167,000 after acquiring an additional 922,622 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Kura Oncology in the second quarter valued at approximately $243,000. Hsbc Holdings PLC increased its stake in Kura Oncology by 6.5% in the second quarter. Hsbc Holdings PLC now owns 94,810 shares of the company’s stock valued at $1,055,000 after purchasing an additional 5,778 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Kura Oncology during the second quarter worth approximately $621,000. Finally, Corient Private Wealth LP acquired a new stake in Kura Oncology during the second quarter worth approximately $1,344,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.